Loading...
Utah Medical Q1 2025 Earnings Report
Utah Medical Products, Inc. reported a decline in net sales, gross profit, operating income, net income, and EPS for Q1 2025 compared to Q1 2024, primarily due to lower OEM sales to PendoTECH.
Key Takeaways
Utah Medical Products, Inc. (UTMD) reported financial results for Q1 2025 that were consistent with its previously announced projections. The company experienced a 14.4% decrease in net sales, an 18.1% decrease in gross profit, an 18.8% decrease in operating income, a 23.1% decrease in net income, and a 16.0% decrease in EPS compared to Q1 2024. The decline was largely attributed to a significant drop in OEM sales to PendoTECH.
Net sales decreased by 14.4% in Q1 2025 compared to Q1 2024, primarily due to a $1,476,000 reduction in OEM sales to PendoTECH.
Gross Profit declined by 18.1%, with the Gross Profit Margin decreasing by almost three percentage points due to manufacturing overhead costs not declining proportionally to sales.
Net Income was 23.1% lower than in Q1 2024, influenced by a higher consolidated income tax provision rate of 21.2% in Q1 2025.
Despite the decline in net income, EPS decreased by a smaller 16.0% due to fewer diluted shares outstanding, resulting from share repurchases.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Management expects revenues to be consistent with Q1 2025 during the remainder of the year, projecting a similar percentage decline in GPM for the year as a whole. The company's operating performance in Q1 2025 is seen as consistent with achieving its financial performance projections for the calendar year 2025.
Positive Outlook
- Financial results consistent with previously announced projections for calendar year 2025.
- Domestic sales, excluding PendoTECH, were 9% higher.
- Recovery of NICU device sales due to improved supply chain.
- Domestic Filshie device sales appear to have stabilized.
- Strong balance sheet with no debt and increased cash and investments.
Challenges Ahead
- Overall revenues declined by 14.4% compared to Q1 2024.
- Significant decline in OEM sales to PendoTECH, accounting for 91% of the total sales decline.
- Gross Profit Margin decreased due to manufacturing overhead costs not declining proportionally to sales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...